Whether to invest and how much to invest, in pre-launch and launch, is a key question facing the leadership teams and boards of emerging biopharma that are considering a “go-it-alone” strategy instead of, or in addition to, a potential late stage strategic exit.
While most emerging biopharma will partner or out-license late stage assets prior to launch, increasingly, companies see it as a value optimizing strategy to retain US rights and pursue a "go-it-alone" launch strategy thus creating a tension between cash-preservation and readiness to launch effectiveness. This session looks to answer the following: Will potential acquirers see an asset as having reduced commercialization risk and higher value when the emerging pharma can communicate a compelling product launch strategy supported by a cross-functional launch activity plan, robust commercial organization design and the resources necessary to launch effectively? Or, do they just want the asset?
Session ID: 22063